Ontology highlight
ABSTRACT:
SUBMITTER: Zeng Y
PROVIDER: S-EPMC9020767 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
Zeng Yue Y Feng Yuanqing Y Fu Guihua G Jiang Junlan J Liu Xiaohan X Pan Yue Y Hu Chunhong C Liu Xianling X Wu Fang F
Frontiers in pharmacology 20220406
The acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is inevitable and heterogeneous. The strategies to overcome acquired resistance are significant. For patients with secondary T790M-positive after early generation EGFR-TKIs, osimertinib is the standard second-line therapy. In patients resistant to prior early generation EGFR-TKIs, the acquired T790M mutation overlaps with other driver gene resistance, such as HER2-and MET amplification, accounting ...[more]